CNMD vs ALMR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CNMD · ConMed$51.50 ▼ 2.52%
ALMR · Alamar Biosciences$28.05 ▲ 4.26%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CNMD +31.8%
- ALMR +27.5%
Head to head
| Metric | CNMD | ALMR |
|---|---|---|
| Price | $51.50 | $28.05 |
| Change today | ▼ 2.52% | ▲ 4.26% |
| Market cap | $1.53B | $1.95B |
| Return, 3 months | +4.1% | +0.2% |
| Return, year to date | +26.8% | – |
| Return, 1 year | +17.1% | – |
| P/E (TTM) | 21.4 | – |
| P/B | 1.4 | 6.4 |
| P/E percentile vs own 5y | 40th | 43rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -0.7% | +82.1% |
| Net profit growth (YoY) | +592.4% | -87.9% |
| Gross margin | 57.6% | 58.7% |
| Operating margin | 9.9% | -40.6% |
| Net margin | 5.4% | -49.5% |
| Return on equity | 7.1% | -15.9% |
| Analyst target vs. price | -3.9% | +16.5% |
| Analyst buy share | 0% | 67% |
| RSI (14) | 61 | 46 |
| 30-day volatility | 55.2% | 115.2% |
| Max drawdown, 1 year | -32.2% | -38.3% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ALMR is the largest of the group by market value.
- ALMR is growing revenue fastest.
- CNMD keeps the most profit per dollar of sales.
- CNMD has been the calmest stock over the last 30 days.